RT Journal Article
SR Electronic
T1 Supplementing the National Early Warning Score (NEWS2) for anticipating early deterioration among patients with COVID-19 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.24.20078006
DO 10.1101/2020.04.24.20078006
A1 Carr, Ewan
A1 Bendayan, Rebecca
A1 O’Gallagher, Kevin
A1 Bean, Daniel
A1 Pickles, Andrew
A1 Stahl, Daniel
A1 Zakeri, Rosita
A1 Searle, Thomas
A1 Shek, Anthony
A1 Kraljevic, Zeljko
A1 Teo, James T.
A1 Shah, Ajay M.
A1 Dobson, Richard JB
YR 2020
UL http://medrxiv.org/content/early/2020/04/29/2020.04.24.20078006.abstract
AB Importance An early minimally symptomatic phase is often followed by deterioration in patients with COVID-19 infection. This study shows that the addition of age and a minimal set of common blood tests taken in patients on admission to hospital significantly improves the National Early Warning Score (NEWS2) for risk-stratification of severe COVID disease.Objective To supplement the NEWS2 score with a small number of easily obtained additional demographic, physiological and blood variables indicative of severity of COVID-19 infection.Design Retrospective observational cohort with internal and temporal held-out external validation.Setting Acute secondary care.Participants 708 patients admitted to an acute multi-site UK NHS hospital with confirmed COVID-19 disease from 1st March to 5th April 2020.Intervention Not applicable.Main outcome and measures The primary outcome was patient status at 14 days after symptom onset categorised as severe disease (WHO-COVID-19 Outcomes Scales 6-8: i.e. transferred to intensive care unit or death). 218 of the 708 patients reached the primary end point. A range of physiological and blood biomarkers were assessed for their association with the primary outcome. Adjustments included age, gender, ethnicity and comorbidities (hypertension, diabetes, heart, respiratory and kidney diseases).Results NEWS2 total score was a weak predictor for severity of COVID-19 infection at 14 days (internally validated AUC = 0.628). The addition of age and common blood tests (CRP, neutrophil count, estimated GFR and albumin) provided substantial improvements to a risk stratification model but performance was still only moderate (AUC = 0.75). Common comorbidities hypertension, diabetes, heart, respiratory and kidney diseases have minor additional predictive value.Conclusions and relevance Adding age and a minimal set of common blood parameters to NEWS2 improves the risk stratification of patients likely to develop severe COVID-19 outcomes. The addition of a few common parameters is likely to be much easier to implement in a short time-scale than a novel risk-scoring system.Competing Interest StatementJTHT received research support and funding from InnovateUK, Bristol-Myers-Squibb, iRhythm Technologies, and holds shares <£5,000 in Glaxo Smithkline and Biogen.Funding StatementDMB is funded by a UKRI Innovation Fellowship as part of Health Data Research UK MR/S00310X/1 (https://www.hdruk.ac.uk). RB is funded in part by grant MR/R016372/1 for the King’s College London MRC Skills Development Fellowship programme funded by the UK Medical Research Council (MRC, https://mrc.ukri.org) and by grant IS-BRC-1215-20018 for the National Institute for Health Research (NIHR, https://www.nihr.ac.uk) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. RJBD is supported by: 1. Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust. 2. The BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA; it is chaired by DE Grobbee and SD Anker, partnering with 20 academic and industry partners and ESC. 3. The National Institute for Health Research University College London Hospitals Biomedical Research Centre. 4. National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. KO’G is supported by an MRC Clinical Training Fellowship. RZ is supported by a King’s Prize Fellowship. AS is supported by a King’s Medical Research Trust studentship. KO is supported by grant MR/R017751/1 AMS is supported by the British Heart Foundation (CH/1999001/11735), the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s & St Thomas’ NHS Foundation Trust and King’s College London (IS-BRC-1215-20006), and the Fondation Leducq. AP is partially supported by NIHR NF-SI-0617-10120. This work was supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC) Clinical and Research Informatics Unit (CRIU), NIHR Health Informatics Collaborative (HIC), and by awards establishing the Institute of Health Informatics at University College London (UCL). This work was also supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust. This paper represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centres at South London and Maudsley NHS Foundation Trust, and Guy’s & St Thomas’ NHS Foundation Trust, both with King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would also like to thank all the clinicians managing the patients, the patient experts of the KERRI committee, Professor Irene Higginson, Professor Alastair Baker, Professor Jules Wendon, Dan Persson and Damian Lewsley for their support. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not publicly available.